key: cord-0952637-gxeoawqj
authors: Bakir Ekinci, Pinar; Kara, Emre; Er, Ahmet Gorkem; Inkaya, Ahmet Cagkan; Demirkan, Kutay; Uzun, Omrum
title: Challenge in treating COVID‐19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels
date: 2021-06-26
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14953
sha: dd21a65d9b7af1e1b9fe66b0a33589f48a7312c4
doc_id: 952637
cord_uid: gxeoawqj

nan

inflammation may be the possible triggered factor in these patients.

Therefore, voriconazole levels may be monitored more frequently in COVID-19 patients, especially during the inflammatory phase. Additional pharmacokinetic studies are warranted in COVID-19 patient population to determine the appropriate dosing of voriconazole to assure therapeutic trough levels.

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020

ECMM/ISHAM consensus criteria for research and clinical guidance

Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

Inflammation is associated with voriconazole trough concentrations

Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9

ACKNOWLEDGMENTS P.B.E. was a major contributor in the study design, data analysis, result interpretation. E.K. and A.C. _ I. contributed to design, analysis, interpretation of data, and revising the manuscript. A.G.E. contributed to writing and revising the manuscript. K.D. and O.U. critically reviewed the manuscript for important intellectual content. All authors read and approved the final manuscript.

The authors have no conflicts of interest to declare.